Cepheid Gains CE Mark for Respiratory Panel

The Xpert Respiratory Panel detects 13 respiratory pathogens from one swab and will begin shipping to CE-mark-accepting countries in the coming weeks.

Updated on Nov. 11, 2026 in Diseases — General

Matte white benchtop diagnostic instrument with a sealed cartridge in its slot beside a swab stick on a steel tray in a clean laboratory.
Cepheid received CE marking under the EU's In Vitro Diagnostic Regulation for its Xpert Respiratory Panel, which detects 13 respiratory pathogens from one swab. AI Illustration. Upload story photo >

Live Poll

Do you trust your doctor to correctly diagnose a respiratory infection?

Cepheid has achieved CE marking under the EU's In Vitro Diagnostic Regulation (IVDR) for its Xpert Respiratory Panel, a multiplex PCR test that detects 13 common viral and bacterial respiratory pathogens from a single nasopharyngeal swab. The test will begin shipping to countries accepting the CE mark in the coming weeks.

Why it matters

Many acute respiratory infections present with overlapping symptoms such as fever, cough and sore throat, making clinical assessment difficult. A test that identifies multiple pathogens at once may help clinicians select appropriate care for patients, including children, older adults and immunocompromised individuals who face higher risk of complications.

The CE mark is a regulatory approval under the EU's IVDR rather than a clinical efficacy result, and the source does not provide sensitivity or specificity figures. For context, influenza alone causes up to 50 million symptomatic cases and 15,000 to 70,000 deaths in Europe in a typical season.

The players

Cepheid

A U.S.-based molecular diagnostics company known for its GeneXpert platform, which is widely used for rapid infectious disease testing in clinical and public health settings.

Danaher

A global life sciences and diagnostics conglomerate that owns Cepheid and operates across biotechnology, life sciences tools and clinical diagnostics.

The details

The panel runs on existing GeneXpert systems, giving providers a way to choose between low-, mid- and multiplex testing for each patient. Cepheid says the test requires less than one minute of hands-on time while delivering on-demand results.

Timeline

  1. November 11, 2026: Cepheid announces CE marking for the Xpert Respiratory Panel.

  2. In the coming weeks: Shipments begin to countries accepting the CE mark.

Health Landscape

Multiplex respiratory PCR panels, led by products such as the BioFire FilmArray Respiratory Panel, have made single-swab detection of many pathogens a established option in clinical laboratories. The Xpert Respiratory Panel extends that approach to Cepheid's GeneXpert platform, which is already installed across many healthcare sites.

A single swab test covering 13 respiratory pathogens could reduce the need for multiple separate tests when a patient presents with fever, cough or sore throat. Shipments are expected in the coming weeks, so availability will depend on each country's acceptance of the CE mark and local procurement.

The takeaway

Testing for many respiratory pathogens at once may reduce delays in identifying the cause of seasonal illness. Patients should discuss any test with their clinician, since results are read alongside symptoms and other clinical findings.

Further reading

Explore more on Diseases — General to see how respiratory infections and their diagnosis are covered across the health landscape.

Source note: This article includes information reported by Pharmabiz.

Live Poll

Do you trust your doctor to correctly diagnose a respiratory infection?